贲门失弛缓症
医学
肌切开术
胃肠病学
食管
内科学
内窥镜检查
普通外科
作者
Kazuya Takahashi,Hiroki Sato,Yuto Shimamura,Hirofumi Abe,Hironari Shiwaku,Junya Shiota,Chiaki Sato,Kenta Hamada,Masaki Ominami,Yoshitaka Hata,Hisashi Fukuda,Ryo Ogawa,Jun Nakamura,Tetsuya Tatsuta,Yuichiro Ikebuchi,Hiroshi Yokomichi,Shuji Terai,Haruhiro Inoue
摘要
Objectives High‐resolution manometry (HRM) and esophagography are used for achalasia diagnosis; however, achalasia phenotypes combining esophageal motility and morphology are unknown. Moreover, predicting treatment outcomes of peroral endoscopic myotomy (POEM) in treatment‐naïve patients remains an unmet need. Methods In this multicenter cohort study, we included 1824 treatment‐naïve patients diagnosed with achalasia. In total, 1778 patients underwent POEM. Clustering by machine learning was conducted to identify achalasia phenotypes using patients' demographic data, including age, sex, disease duration, body mass index, and HRM/esophagography findings. Machine learning models were developed to predict persistent symptoms (Eckardt score ≥3) and reflux esophagitis (RE) (Los Angeles grades A–D) after POEM. Results Machine learning identified three achalasia phenotypes: phenotype 1, type I achalasia with a dilated esophagus ( n = 676; 37.0%); phenotype 2, type II achalasia with a dilated esophagus ( n = 203; 11.1%); and phenotype 3, late‐onset type I–III achalasia with a nondilated esophagus ( n = 619, 33.9%). Types I and II achalasia in phenotypes 1 and 2 exhibited different clinical characteristics from those in phenotype 3, implying different pathophysiologies within the same HRM diagnosis. A predictive model for persistent symptoms exhibited an area under the curve of 0.70. Pre‐POEM Eckardt score ≥6 was the greatest contributing factor for persistent symptoms. The area under the curve for post‐POEM RE was 0.61. Conclusion Achalasia phenotypes combining esophageal motility and morphology indicated multiple disease pathophysiologies. Machine learning helped develop an optimal risk stratification model for persistent symptoms with novel insights into treatment resistance factors.
科研通智能强力驱动
Strongly Powered by AbleSci AI